2-(2,2-Dihydroxyethyl)-2-hydroxybutanedioic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(2,2-Dihydroxyethyl)-2-hydroxybutanedioic acid
• 化学式: C₆H₁₀O₇
• 分子量: 194.14
• InChiKey: RULAAQMFEIYYES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Compositions for treating the hair
  申请人：L'OREAL

  公开号：US10828244B2

  公开（公告）日：2020-11-10

  The disclosure relates to compositions for treating keratinous substrates, such as the hair, comprising 2-(2-aminoethoxy)ethanol and at least one carboxylic acid, as well as systems and methods for treating keratinous substrates with the compositions.

  本公开涉及用于处理角质基质（如头发）的包含 2-（2-氨基乙氧基）乙醇和至少一种羧酸的组合物，以及用该组合物处理角质基质的系统和方法。
• HYALURONIC ACID DERMAL FILLERS CROSSLINKED WITH CITRIC ACID, METHOD FOR MAKING SAME AND USES THEREOF
  申请人：Anteis SA

  公开号：EP3538066B1

  公开（公告）日：2021-12-29
• LIPID DELIVERY FORMULATIONS
  申请人：Brown Bob D.

  公开号：US20130225663A1

  公开（公告）日：2013-08-29

  The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.
• US9320798B2
  申请人：——

  公开号：US9320798B2

  公开（公告）日：2016-04-26
• [EN] LIPID DELIVERY FORMULATIONS<br/>[FR] FORMULATIONS D'ADMINISTRATION DE LIPIDE
  申请人：DICERNA PHARMACEUTICALS INC

  公开号：WO2011109294A1

  公开（公告）日：2011-09-09

  The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.